Melinta Therapeutics, Inc.

CorMedix has found a synergistic partner in Melinta Therapeutics, paying $300 million to buy out its New Jersey neighbor. New Jersey biopharma CorMedix entered its commercial phase in 2023 with a long-awaited approval of DefenCath, a combination treatment that reduces the risk of catheter-related bloodstream infections (CRBSIs) for those with kidney disease.Two years later, CorMedix is expanding its portfolio of infectious disease products for hospitalized patients with the acquisition of another New Jersey-based commercial-stage company, Melinta Therapeutics, for $300 million.The 25-year-old private firm brings seven marketed products, including six for infectious diseases, led by its top seller Rezzayo, which treats potentially fatal yeast infections in the bloodstream. The antifungal was also approved in 2023.“This deal is transformational for CorMedix, creating a fully diversified specialty pharmaceutical company with a broad portfolio of commercial and pipeline products concentrated in the acute care and anti-infectives area,” CEO Joe Todisco said in a Thursday conference call.Todisco added that the companies’ operational infrastructures are “highly synergistic,” which CorMedix estimates will lead to between $35 million and $45 million in annual savings.CorMedix projects Melinta products will generate between $125 million and $135 million in revenue this year. The company also expects future growth from Rezzayo with an anticipated expansion as a prophylaxis of invasive fungal diseases in patients undergoing blood and marrow transplants.“We estimate that, if approved, peak annual sales potential in this indication could exceed $200 million,” Todisco said. The companies expect to close the transaction as early as Sept. 1.“Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability,” Melinta CEO Christine Ann Miller said in a release. “CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization.” As for DefenCath, the company is projecting sales of between $180 million and $200 million this year, thanks largely to a deal with a Large Dialysis Organization (LDO), which CorMedix announced two weeks ago. With the sales boost combined with the acquisition, CorMedix is projecting 2025 revenue between $305 million and $335 million.CorMedix also has expansion plans for DefenCath as a treatment to reduce central-line bloodstream infections (CLABSIs) for those receiving total parental nutrition through a central venous catheter. A phase 3 study is underway with plans to submit for approval in late 2026 or early 2027.

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN ® and REZZAYO™. The proposed acquisition will expand CorMedix’s team and commercial platform, and increase the commercial portfolio with six marketed, highly differentiated, hospital- and clinic-focused infectious disease products, including REZZAYO™ (rezafungin for injection), MINOCIN ® (minocycline) for Injection, VABOMERE ® (meropenem and vaborbactam), KIMYRSA ® (oritavancin), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), and an additional well-established cardiovascular product, TOPROL-XL ® (metoprolol succinate). REZZAYO™ is currently approved for the treatment of candidemia and invasive candidiasis in adults, with an ongoing Phase III study for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation. The completion of the Phase III study for REZZAYO™ is expected in 1H 2026. “This acquisition is a transformational step in the evolution of CorMedix, providing an attractive revenue base of highly synergistic assets, as well as multiple opportunities to drive future growth. We are excited to acquire Melinta, which enables us to expand our product portfolio in the hospital space while delivering therapies to patients with high unmet need,” said Joseph Todisco, CEO of CorMedix Inc.   “I would like to congratulate Christine Ann Miller, Melinta Therapeutics President & CEO, on building a high-performing organization. The combination with Melinta creates a formidable and diversified specialty platform with a deep and experienced team in the hospital acute care and infectious disease arena. This transaction reflects the type of high-impact, cash-flow generating opportunities we are targeting and strengthens our position to further expand, as we strive to create shareholder value through both organic growth and additional acquisitions in the future.” “The synergistic combination of Melinta and CorMedix represents an exciting new chapter in our company’s evolution,” said Christine Ann Miller, President and CEO of Melinta Therapeutics. “Over the past five years, we have built a robust commercial infrastructure with a high-performing team, deep expertise, and relationships within the hospital and acute care ecosystem, while achieving significant revenue growth and sustained profitability. CorMedix recognizes not just our innovative therapies, but the exceptional capabilities of our organization. I’m confident that Melinta’s commercial excellence and proven track record will augment CorMedix’s team and track record of operational execution and success, to create an even stronger platform for future growth.” Strategic and Financial Benefits Terms and Financing Under the terms of the agreement, which has been approved by the CorMedix and Melinta Board of Directors respectively, CorMedix will pay $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders of Deerfield Management Company, L.P. (“Deerfield”). The cash consideration will be funded by a combination of CorMedix’s existing cash on hand and the proceeds of a $150 million convertible debt financing with high quality healthcare focused institutional investors, including Deerfield, the terms of which will be described in a Current Report on Form 8-K to be filed by the Company today. The agreement contains an additional regulatory milestone of up to $25 million (payable in cash or shares at CorMedix’s election) for the FDA approval of the expanded indication of REZZAYO™ for prophylaxis of invasive fungal infections in adults undergoing allogeneic blood and marrow transplantation, if this milestone event is achieved by June 30, 2029. Furthermore, the agreement includes tiered royalties on REZZAYO™ U.S. net sales and low-single-digit royalties on MINOCIN ® U.S. net sales. The transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the ‘HSR Act’). The Company expects the transaction to close as early as September 1, 2025. Full Year Financial Guidance Advisors Moelis & Company LLC is acting as exclusive financial advisor for CorMedix in connection with the acquisition of Melinta and sole placement agent for convertible debt financing. Willkie Farr & Gallagher LLP is acting as legal advisor to CorMedix in connection with the acquisition of Melinta and the convertible debt financing. RBC Capital Markets is acting as a financial advisor to CorMedix in connection with the convertible debt financing. Goodwin Procter LLP is acting as a legal advisor to Moelis & Company LLC for the convertible debt financing. Conference Call and Webcast Information Management will host a conference call and a live webcast today, August 7, 2025, at 8:30 a.m. ET, to discuss the transaction and CorMedix’s second quarter 2025 financial results. The conference call can be accessed by dialing 1-844-676-2922 from the United States or 1-412-634-6840 internationally. The live webcast will be accessible in the “ Presentations & Events ” section of the CorMedix Investor Relations website or using the following Webcast Link . About CorMedix CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath ® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath ® in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath ® as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com . About Melinta Melinta Therapeutics is a biopharmaceutical company dedicated to providing innovative therapies to people impacted by acute and life-threatening illnesses. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. Our portfolio currently includes seven commercial-stage products: MINOCIN ® (minocycline), REZZAYO™ (rezafungin), VABOMERE ® (meropenem and vaborbactam), ORBACTIV™ (oritavancin), BAXDELA ® (delafloxacin), KIMYRSA ® (oritavancin), and TOPROL-XL ® (metoprolol succinate). For more information about Melinta Therapeutics, our commitment to patients, and to learn about our portfolio of therapies, visit www.melinta.com . SOURCE: CorMedix

Plus, news about Assembly Biosciences, Vaxcyte, CorMedix, Melinta Therapeutics, Innogen, Sana Biotechnology, SNIPR Biome, Voyager Therapeutics, Gilead, Arcus, Travere and Alltrna: XtalPi to work with DoveTree Medicines: The Chinese AI drug discovery company got $51 million upfront, so that DoveTree can get global R&D and commercial rights for drugs made from the partnership. There’s an additional $49 million of near-term payments on the table, as well as milestones and royalties that could balloon up to $5.9 billion. The disease targets include immunology, inflammation, neurology, oncology and metabolic disease. DoveTree was founded by biotech veteran Greg Verdine. — Reynald Castaneda Regenxbio amends eye deal with AbbVie: The companies first teamed up in 2021 to examine surabgene lomparvovec as a treatment for several eye diseases. The biotech now plans to initiate a Phase 2b/3 study in diabetic retinopathy, noting that it will receive $100 million when the first patient is dosed in that trial and another $100 million if a patient is dosed in the second Phase 3 study. Regenxbio is responsible for paying for the Phase 2b portion of the trial, while AbbVie will cover the costs of a new Phase 3 trial for sura-vec in wet AMD. — Jaimy Lee Assembly Biosciences sees safety signal in hepatitis delta study: The company said a grade 2 liver enzyme elevation was recorded in a healthy volunteer who received the highest single dose level of ABI-6250, its experimental hepatitis delta virus entry inhibitor. Assembly said that “further pharmacological assessment” would be done as it prepares for Phase 2 studies. The company noted the studies would “explore potential factors associated with these elevations given the role of ABI-6250’s target as a bile acid transporter.” — Lei Lei Wu Vaxcyte prunes early-stage pipeline: The company is pausing the advancement of two prophylactic vaccine candidates into the clinic — VAX-A1 for strep infections and VAX-GI for shigella. It is also discontinuing a therapeutic vaccine called VAX-PG for periodontal disease. Vaxcyte said the changes should allow it to focus on its pneumococcal conjugate vaccine. — Ayisha Sharma CorMedix to buy Melinta Therapeutics: The New Jersey biotech companies will come together in a deal that sees CorMedix pay $260 million in cash and $40 million in equity to “Melinta shareholders of Deerfield Management Company.” Deerfield acquired Melinta pursuant to a Chapter 11 reorganization about five years ago. CorMedix said the deal will expand its “reach in infectious disease.” — Kyle LaHucik Innogen’s Hong Kong IPO: The biotech expects proceeds of HK$610 million (about $77 million) from its initial public offering, according to an HKEX filing . The 11-year-old biotech markets a type 2 diabetes drug in China and is also working in MASH, obesity and other areas. DualityBio , Hengrui Pharma and other biotechs have gone public on the Hong Kong exchange this year. — Kyle LaHucik Sana Biotechnology’s $75M offering: The biotech is selling about 21 million shares at $3.35 apiece. — Jaimy Lee SNIPR Biome raises $40.7M Series B: The Copenhagen-based biotech will use the funds to support the development of a CRISPR/Cas therapy for airway infections caused by Pseudomonas aeruginosa bacteria in cystic fibrosis patients, among other programs. The fundraise was supported by both new and existing investors. — Ayisha Sharma Voyager Therapeutics restructures: The company executed “cost-savings measures” in the first half of the year that included changes in trial designs, outsourcing and an undisclosed number of workforce cuts, according to a SEC filing . The move extends its cash runway into 2028, as per a press release . Voyager had $262 million in cash, cash equivalents and marketable securities as of June 30. It had 172 staffers at the end of 2024. — Reynald Castaneda Gilead drops Arcus cancer drug: The partners have decided not to advance etrumadenant into registrational development for colorectal cancer, despite the FDA confirming a potential path forward. Gilead returned its license for the A2a/A2b receptor antagonist in June. It paid $725 million to exercise options for etrumadenant and several other Arcus drugs back in 2021. — Ayisha Sharma Travere gets $17.5M from CSL Vifor: The milestone payment stems from Filspari’s conversion from a conditional to standard approval in the EU and UK. Filspari is Travere’s treatment for IgA nephropathy, which received conditional approvals in Europe last year. The drug also won full FDA approval in 2024, following an initial accelerated approval in 2023. — Lei Lei Wu Flagship’s Alltrna lays off 12% of staff: The biotech let go of eight employees as it aims to get its engineered tRNA drug candidate into the clinic. “Our strategy and vision remain unchanged,” an Alltrna spokesperson said in a statement. — Jaimy Lee